Technology
Health
Biotechnology

Neon Therapeutics

$5.17
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell NTGN and other stocks, options, ETFs, and crypto commission-free!

About

Neon Therapeutics, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. Read More The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA.

Employees
102
Headquarters
Cambridge, Massachusetts
Founded
2013
Market Cap
146.38M
Price-Earnings Ratio
ā€”
Dividend Yield
ā€”
Average Volume
141.69K
High Today
$5.24
Low Today
$4.85
Open Price
$5.14
Volume
126.50K
52 Week High
$16.23
52 Week Low
$4.20

Collections

Technology
Health
Biotechnology
Therapy
Cancer Prevention
Photovoltaics
Medical
Renewable Energy Generation

News

Associated PressMar 11

Neon Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today reported financial results for the fourth quarter and full-year ended December 31, 2018 and provided a business update. ā€œ2018 was a transformative year for Neon, highlighted by significant advances in applying our insights into neoantigen biology not only to our vaccine product candidates but also to our emerging cellular thera...

92
Associated PressFeb 28

Neon Therapeutics to Present at the American Association for Cancer Research Annual Meeting

This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced upcoming presentations at the Ameri...

6

Earnings

-$0.84
-$0.78
-$0.73
-$0.67
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
ā€”
Actual
Expected May 2, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.